Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0263)
| Name |
Atractylodin
|
||||
|---|---|---|---|---|---|
| Synonyms |
Atractylodin; 55290-63-6; Atractydin; 2-[(1E,7E)-nona-1,7-dien-3,5-diynyl]furan; V73E8B6UAC; (E,E)-2-(1,7-Nonadiene-3,5-diynyl)furan; 2-(NONA-1,7-DIEN-3,5-DIYN-1-YL)FURAN; Furan, 2-(1,7-nonadiene-3,5-diynyl)-, (E,E)-; 2-((1E,7E)-Nona-1,7-dien-3,5-diyn-1-yl)furan-1-yl)furan; 97235-99-9; UNII-V73E8B6UAC; CHEBI:80795; GRBKWAXRYIITKG-QFMFQGICSA-N; DTXSID901019940; BCP28324; HY-N0238; MFCD01075143; AKOS006281381; CS-3672; AC-34063; AS-82932; A14776; C16918; Q-100629; Q27149839; 3,5-BIS(TRIFLUOROMETHYL)-4-CHLORO-NITROBENZENE; Furan, 2-[(1E,7E)-1,7-nonadiene-3,5-diyn-1-yl]-
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C13H10O
|
||||
| IUPAC Name |
2-[(1E,7E)-nona-1,7-dien-3,5-diynyl]furan
|
||||
| Canonical SMILES |
CC=CC#CC#CC=CC1=CC=CO1
|
||||
| InChI |
InChI=1S/C13H10O/c1-2-3-4-5-6-7-8-10-13-11-9-12-14-13/h2-3,8-12H,1H3/b3-2+,10-8+
|
||||
| InChIKey |
GRBKWAXRYIITKG-QFMFQGICSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Transferrin receptor protein 1 (TFRC)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Marker/Suppressor/Driver | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
| Cell migration | ||||
| Cell invasion | ||||
| In Vitro Model | Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 |
| Hccm (Human hepatocellular carcinoma cells) | ||||
| Response regulation | Atractylodin can inhibit the proliferation, migration, and invasion of Huh7 and Hccm liver cancer cells, and induce cell apoptosis and cell cycle arrest. In addition, atractylodin may induce ferroptosis in hepatocellular carcinoma cells by inhibiting the expression of GPX4 and FTL proteins, and up-regulating the expression of ACSL4 and TFR1 proteins. | |||
Phospholipid hydroperoxide glutathione peroxidase (GPX4)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
| Cell migration | ||||
| Cell invasion | ||||
| In Vitro Model | Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 |
| Hccm (Human hepatocellular carcinoma cells) | ||||
| Response regulation | Atractylodin can inhibit the proliferation, migration, and invasion of Huh7 and Hccm liver cancer cells, and induce cell apoptosis and cell cycle arrest. In addition, atractylodin may induce ferroptosis in hepatocellular carcinoma cells by inhibiting the expression of GPX4 and FTL proteins, and up-regulating the expression of ACSL4 and TFR1 proteins. | |||
Long-chain-fatty-acid--CoA ligase 4 (ACSL4)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Driver | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
| Cell migration | ||||
| Cell invasion | ||||
| In Vitro Model | Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 |
| Hccm (Human hepatocellular carcinoma cells) | ||||
| Response regulation | Atractylodin can inhibit the proliferation, migration, and invasion of Huh7 and Hccm liver cancer cells, and induce cell apoptosis and cell cycle arrest. In addition, atractylodin may induce ferroptosis in hepatocellular carcinoma cells by inhibiting the expression of GPX4 and FTL proteins, and up-regulating the expression of ACSL4 and TFR1 proteins. | |||
Ferritin light chain (FTL)
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Target for Ferroptosis | Suppressor | |||
| Responsed Disease | Hepatocellular carcinoma | ICD-11: 2C12 | ||
| Pathway Response | Ferroptosis | hsa04216 | ||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell apoptosis | ||||
| Cell proliferation | ||||
| Cell migration | ||||
| Cell invasion | ||||
| In Vitro Model | Huh-7 cells | Hepatocellular carcinoma | Homo sapiens | CVCL_0336 |
| Hccm (Human hepatocellular carcinoma cells) | ||||
| Response regulation | Atractylodin can inhibit the proliferation, migration, and invasion of Huh7 and Hccm liver cancer cells, and induce cell apoptosis and cell cycle arrest. In addition, atractylodin may induce ferroptosis in hepatocellular carcinoma cells by inhibiting the expression of GPX4 and FTL proteins, and up-regulating the expression of ACSL4 and TFR1 proteins. | |||